DENVER, Jan. 06, 2017 -- Air Methods Corporation (Nasdaq:AIRM), the global leader in air medical transportation, today reported preliminary patient transport and tourism passenger data for the month of December 2016.
| Air Medical | Dec-16 | Dec-15 | YOY Change (%) | 4Q16 | 4Q15 | YOY Change (%) | ||
| Transports | 5,142 | 4,735 | 8.6 | % | 17,571 | 15,817 | 11.1 | % |
| Transports + Weather Cancellations | 8,285 | 7,852 | 5.5 | % | 23,924 | 22,945 | 4.3 | % |
| Same-Base Transports (SBTs) | 4,447 | 4,534 | (1.9 | %) | 15,107 | 14,891 | 1.5 | % |
| SBT + Weather Cancellations | 7,310 | 7,498 | (2.5 | %) | 20,837 | 21,664 | (3.8 | %) |
| Tourism | Dec-16 | Dec-15 | YOY Change (%) | 4Q16 | 4Q15 | YOY Change (%) | ||
| Passengers | 30,149 | 32,256 | (6.5 | %) | 101,623 | 103,261 | (1.6 | %) |
Aaron Todd, CEO of Air Methods, stated, “Tourism volumes were impacted negatively by weather in both our Sundance and Blue Hawaiian operations. We anticipate the passenger count would have been roughly flat in December were it not for weather.”
About Air Methods Corporation
Air Methods Corporation (www.airmethods.com) is the global leader in air medical transportation. The Air Medical Services Division is the largest provider of air medical transport services in the United States. The United Rotorcraft Division specializes in the design and manufacture of aeromedical and aerospace technology. The Tourism Division is comprised of Sundance Helicopters, Inc. and Blue Hawaiian Helicopters, which provide helicopter tours and charter flights in the Las Vegas/Grand Canyon region and Hawaii, respectively. Air Methods’ fleet of owned, leased or maintained aircraft features approximately 500 helicopters and fixed wing aircraft.
Forward Looking Statements: Forward-looking statements in this news release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are “forward-looking statements”, including statements we make with regard to preliminary results of (i) total transports, (ii) same-base transports, (iii) weather cancellations, and (iv) tourism passengers for December 2016 are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including but not limited to the Company’s completion of its fourth quarter closing and review procedures and other matters set forth in the Company's filings with the SEC. The Company is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS: Peter P. Csapo, Chief Financial Officer, ([email protected]). Please contact Christina Brodsly Ward at ([email protected]) to be included on the Company’s e-mail distribution list.


Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Apple Turns 50: From Garage Startup to AI Crossroads
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Bank of America's $72.5M Epstein Settlement: What You Need to Know
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 



